David was advisor to a wide range of pharmaceutical, biotechnology, medical device, diagnostic, and dietary supplement clients.
During his career, David advised clients on a variety of regulatory and healthcare issues, including strategies for obtaining FDA product approvals and clearances, recalls, labeling, and claim support for advertising and promotional materials.
David was named among the Daily Journal's "25 Leading Biotech Attorneys" in California and was recognized as one of the leading food and drug regulatory attorneys in the U.S.
David has published many articles about the FDA and pharmaceutical and medical device industries.
David Hoffmeister retired as a partner from Wilson Sonsini Goodrich & Rosati in 2023. He was a senior practitioner in the firm's drug and device regulatory practice as well as the firm’s life sciences group. He was named as one of the "25 Leading Biotech Attorneys" in California by the Daily Journal, and was recognized as one of the leading food and drug regulatory attorneys in the country.
David has more than 25 years of experience in drug and device regulatory and healthcare law matters. He represented pharmaceutical, biotechnology, medical device, diagnostic, and dietary supplement clients, advising them on a variety of regulatory and healthcare issues, such as strategies for obtaining FDA product approvals and clearances, recalls, labeling, and claim support for advertising and promotional materials. He also conducted numerous internal investigations for pharmaceutical and medical device companies involving fraud and abuse, advertising and promotional practices, and clinical research practices.
Earlier in his career, David was senior counsel for drug and device law at Syntex U.S.A., Inc., where his primary focus was advising senior management on worldwide issues affecting the ability of the corporation and its affiliates to develop, manufacture, and distribute pharmaceutical, device, diagnostic, and over-the-counter drugs in compliance with the Federal Food, Drug, and Cosmetics Act, as well as implementing regulations and applicable state and federal healthcare laws.
David Hoffmeister retired as a partner from Wilson Sonsini Goodrich & Rosati in 2023. He was a senior practitioner in the firm's drug and device regulatory practice as well as the firm’s life sciences group. He was named as one of the "25 Leading Biotech Attorneys" in California by the Daily Journal, and was recognized as one of the leading food and drug regulatory attorneys in the country.
David has more than 25 years of experience in drug and device regulatory and healthcare law matters. He represented pharmaceutical, biotechnology, medical device, diagnostic, and dietary supplement clients, advising them on a variety of regulatory and healthcare issues, such as strategies for obtaining FDA product approvals and clearances, recalls, labeling, and claim support for advertising and promotional materials. He also conducted numerous internal investigations for pharmaceutical and medical device companies involving fraud and abuse, advertising and promotional practices, and clinical research practices.
Earlier in his career, David was senior counsel for drug and device law at Syntex U.S.A., Inc., where his primary focus was advising senior management on worldwide issues affecting the ability of the corporation and its affiliates to develop, manufacture, and distribute pharmaceutical, device, diagnostic, and over-the-counter drugs in compliance with the Federal Food, Drug, and Cosmetics Act, as well as implementing regulations and applicable state and federal healthcare laws.
Co-author with G. Ravitz, J. Ravitz, and E. Yin, "Prescription Drug Provisions in the Build Back Better Act," Wilson Sonsini Alert, January 10, 2022
Co-author with P. Gadiock, G. Ravitz, J. Ravitz, and E. Yin, "FDA Issues Draft Transition Plans for Medical Devices Commercialized Pursuant to EUA or Enforcement Discretion Policy During COVID-19 Emergency," Wilson Sonsini Alert, December 23, 2021
Co-author with G. Ravitz, J. Ravitz, and E. Yin, "Prescription Drug Provisions in the Build Back Better Act," Wilson Sonsini Alert, January 10, 2022
Co-author with P. Gadiock, G. Ravitz, J. Ravitz, and E. Yin, "FDA Issues Draft Transition Plans for Medical Devices Commercialized Pursuant to EUA or Enforcement Discretion Policy During COVID-19 Emergency," Wilson Sonsini Alert, December 23, 2021